Eupraxia Pharmaceuticals: Buy Rating Backed by Strong Pipeline Advancements and Robust Financial Position
I'm PortAI, I can summarize articles.
Analyst Brandon Folkes from H.C. Wainwright has reiterated a Buy rating on Eupraxia Pharmaceuticals, maintaining a price target of $12.00. This rating is supported by significant advancements in the company's pipeline, particularly in the EP-104GI program and the Phase 2b RESOLVE trial, which has shown promising results. Eupraxia's strong financial position, with a cash runway until 2028, allows for continued development. The expansion of the trial is expected to enhance its statistical power, further supporting the Buy rating.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments